Evidence map›Paper›PMID 31386727›Full record

ArticleNanoscale2019

Nanopatterning protein antigens to refocus the immune response.

Ammar Arsiwala, Chad Varner, Jessica N McCaffery, Andrew Kell, Geetanjali Pendyala, Ana Castro, Vivek Hariharan, Alberto Moreno, Ravi S Kane

Open access · greenAbstract read
In one paragraph

Article in Nanoscale, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. A multivalentBioengineering & translational medicine · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ammar ArsiwalaSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA - 30332, USA. ravi.kane@chbe.gatech.edu.
Chad Varner
Jessica N McCaffery
Andrew Kell
Geetanjali Pendyala
Ana Castro
Vivek Hariharan
Alberto Moreno
Ravi S Kane
Georgia Institute of Technology · USEmory University · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Development of simianized mice to study the biology of relapsing malaria parasitesR21AI135711 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2018 to 2019
$482k
Zika Virus Vaccines based on Nanoscale Constructs Presenting the Envelope ProteinR21AI129477 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI KANE, RAVI S. · 2017 to 2018
$448k
NIAID NIH HHS R21 AI129477NIAID NIH HHS R21 AI135711NIH HHS P51 OD011132
6 · The paper itself

Abstract

Vaccines for many important diseases remain elusive, and those for others need to be updated frequently. Vaccine efficacy has been hindered by existing sequence diversity in proteins and by newly-acquired mutations that enable escape from vaccine-induced immune responses. To address these limitations, we developed an approach for nanopatterning protein antigens that combines the site-specific incorporation of non-canonical amino acids with chemical modification to focus the immune response on conserved protein regions. We demonstrated the approach using green fluorescent protein (GFP) as a model antigen and with a promising malaria vaccine candidate, Merozoite surface protein 119 (MSP119). Immunization of mice with nanopatterned MSP119 elicited antibodies that recognized MSP119 from heterologous strains, differing in sequence at as many as 21 of 96 residues. Nanopatterning should enable the elicitation of broadly protective antibodies against a wide range of pathogens and toxins.

Indexed as

AnimalsAntibodies, ProtozoanAntigensGreen Fluorescent ProteinsMalaria VaccinesMiceMutagenesisNanostructuresPlasmodium falciparumPolyethylene GlycolsProtozoan ProteinsSingle-Domain AntibodiesAntibodies, ProtozoanAntigensGreen Fluorescent ProteinsMalaria VaccinesPolyethylene GlycolsProtozoan ProteinsSingle-Domain Antibodies

Identifiers

PMID31386727
PMCPMC6705394
OpenAlexW2966299141

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.